Therapeutic Product Immunogenicity Community

 View Only

OSD ON FEB 21st: CHARACTERIZING CD4 T CELL IMMUNE RESPONSES (PART 2)

  • 1.  OSD ON FEB 21st: CHARACTERIZING CD4 T CELL IMMUNE RESPONSES (PART 2)

    Community Leadership
    Posted 02-07-2024 19:38

    Please join us for an Open Scientific Discussion (OSD) hosted by the AAPS Therapeutic Product Immunogenicity (TPI) and Biomarkers and Precision Medicine (BPM) Communities on February 21st, 12 - 1 pm ET on the following topic:

    Characterizing CD4 T Cell Immune Responses (Part 2)

    ·       What are the complementary assays to a CD4 T cell assay for integrated immunogenicity risk assessment?

    ·       What are the key parameters and considerations for preclinical immunogenicity assays?

    ·       How to qualify a CD4 T cell assay?

    Discussion Leaders:

    Sophie Tourdot (Pfizer), Sofie Denies (ImmunXperts), Chloe Ackaert (ImmunXperts), and Sofie Pattyn (ImmunXperts)

    Organized by:  Yi Wen (Lilly), Vibha Jawa (BMS), Carmen Fernández-Metzler (PharmaCadence) and Karen Quadrini (Prothena Biosciences)

     

    We start at 12:00 ET sharp. To avoid interruptions, please dial in before noon and mute yourself until Q&A starts.

    (Please remain on mute unless asking questions)

    When: Wed, Feb 21, 2024, 12 pm – 1 pm ET

    WherePlease join from your computer, tablet or smartphone.
    https://global.gotomeeting.com/join/305789893

    You can also dial in using your phone.
    United States: 
    +1 (872) 240-3412
    Access Code: 305-789-893
    Join from a video-conferencing room or system.
    Dial in or type: 
    67.217.95.2 or inroomlink.goto.com
    Meeting ID: 305 789 893
    Or dial directly: 
    [email protected] or 67.217.95.2##305789893
    New to GoToMeeting? Get the app now and be ready when your first meeting starts:
    https://global.gotomeeting.com/install/305789893

    Please feel free to share with colleagues who may be interested in this topic.

     

    Thank you,

    The Leadership Teams of the AAPS TPI and BPM Communities



    ------------------------------
    Yi Wen Ph.D.
    Sr. Director
    Eli Lilly and Company
    Indianapolis IN
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------